Hosokawa, Shinobu
Ichihara, Eiki http://orcid.org/0000-0002-2966-106X
Harada, Daijiro
Kuyama, Shoichi
Inoue, Koji
Gemba, Kenichi
Ichikawa, Hirohisa
Kato, Yuka
Oda, Naohiro
Oze, Isao
Tamura, Tomoki
Kozuki, Toshiyuki
Umeno, Takahiro
Kubo, Toshio
Hotta, Katsuyuki
Bessho, Akihiro
Maeda, Yoshinobu
Kiura, Katsuyuki
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
https://doi.org/10.1007/s10147-022-02164-2
Article History
Received: 8 February 2022
Accepted: 27 March 2022
First Online: 10 May 2022
Declarations
:
: E. Ichihara has received honoraria from Eli Lilly Japanand research funds from MSD, Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Janssen Pharmaceutical K.K. T. Kubo has received honoraria from Chugai Pharmaceutical Co. Ltd. T. Kozuki has received honoraria from AstraZeneca, Eli Lilly Japan, and Ono Pharmaceutical Co. Ltd., and research funds from MSD, Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd and Merck. S. Kuyama has received honoraria from Chugai Pharmaceutical Co. Ltd. K. Hotta received honoraria from Pfizer, AZ, Chugai, Lilly, Takeda, MSD, BMS, Ono, Taiho, and Boehringer-Ingelheim, and research funds from MSD, AZ, Chugai, Lilly, BMS, and Abbvie outside the submitted work. A. Bessho has received research funds from Ono Pharmaceutical Co. Ltd., AstraZeneca, MSD, and Chugai Pharmaceutical CO. Ltd. Y. Maeda has received honoraria from Novartis and research funds from Otsuka Pharmaceutical Co. Ltd., Eisai, MSD, Asahi Kasei Pharma, Chugai Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Kyowa Kirin, Astellas, Novartis, AstraZeneca, Janssen Pharmaceutical K.K., and Mundipharma K.K. K. Kiura has received honoraria from MSD and research funds from Nippon Kayaku Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Bristol Myers Squibb, Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Shionogi Pharmaceutical Co. Ltd., Boehringer Ingelheim, and MSD.